Technologies investigated for screening in Barrett's oesophagus and OAC
| Study | Year | Technique | No of patients | Design | Findings | Grade |
|---|---|---|---|---|---|---|
| Gerson et al361 | 2009 | Standard OGD | 126 asymptomatic women | Prospective single-centre screening | 6% Barrett's prevalence (all SSBO) | III |
| Rex et al362 | 2003 | Standard OGD | 961 patients undergoing colonoscopy | Prospective multicentre screening | 6.8% Barrett's prevalence (8.3% in symptomatic individuals) | III |
| Jobe et al363 | 2006 | Standard OGD vs TNE | 121 with GORD or known Barrett's | Randomised crossover | Similar prevalence of Barrett's with the two techniques | Ib |
| Shariff et al13 | 2012 | Standard OGD vs TNE | 82 (49 with known Barrett's+33 controls) | Randomised crossover | TNE had 98% sens and 100% spec for diagnosis of Barrett's | Ib |
| Lin et al364 | 2007 | CE followed by OGD | 90 with GORD or known Barrett's | Prospective blinded comparative | CE had 67% sens and 84% spec for diagnosis of Barrett's | III |
| Galmiche et al365 | 2008 | CE followed by OGD | 77 referred for OGD | Prospective blinded comparative | CE had 60% sens and 100% spec for diagnosis of Barrett's | III |
| Ramirez et al366 | 2008 | String CE followed by OGD | 100 with GORD | Prospective blinded comparative | CE had 73% sens and 84% spec for diagnosis of Barrett's | III |
| Kadri et al367 | 2010 | Cytosponge followed by OGD | 501 with GORD | Prospective blinded comparative | CE had 73% sens and 94% spec for diagnosis of Barrett's (≥1 cm) | III |
| Qin et al368 | 1993 | Occult blood bead | 233 825 individuals | Prospective cohort | Sensitivity for upper GI cancer: 3.4% | III |
CE, capsule endoscopy; OAC, oesophageal adenocarcinoma; sens, sensitivity; spec, specificity; SSBO, short segment of Barrett's; TNE, transnasal endoscopy.